Low doses of the neuropeptide Substance P promoted healthy tendon cell development, while high doses drove stem cells toward non-tendon fates and caused tendinosis-like damage in rat tendons.
Dose-dependent switchLow-dose SP (0.5 nmol) enhanced tendon formation while high-dose SP (5.0 nmol) induced tendinosis-like damage in the same rat model
What the researchers found
Both low (0.1 nM) and high (1.0 nM) concentrations of Substance P enhanced tendon-derived stem cell (TDSC) proliferation in vitro. However, low-dose SP induced tenocyte-related gene expression (promoting healthy tendon cell identity), while high-dose SP induced non-tenocyte genes including PPARγ (a fat cell marker) and collagen type II (a cartilage marker).
In vivo, injecting low-dose SP (0.5 nmol) into rat patella tendons enhanced tenogenesis compared to both saline controls and high-dose SP. High-dose SP (5.0 nmol) induced tendinosis-like changes in the tendon. These findings demonstrate a clear dose-dependent switch from therapeutic to pathological effects.
Why it matters
Tendinopathy is extremely common and difficult to treat, affecting athletes and workers alike. Substance P levels are elevated in painful tendons, but it was unclear whether SP is part of the problem or part of the healing response. This study resolves that paradox: SP is both, depending on concentration. This has direct implications for developing peptide-based tendon therapies and understanding why some tendon injuries become chronic.
How the study worked
In vitro: tendon-derived stem cells were cultured with SP at 0.1 nM and 1.0 nM concentrations; proliferation capacity and gene expression (tenocyte vs. non-tenocyte markers) were measured. In vivo: SP was injected into rat patella tendons at 0.5 nmol and 5.0 nmol doses; histological changes were assessed compared to saline-injected controls.
What this study cannot tell us
The study used rat models and isolated stem cells, which may not fully replicate human tendon biology. The specific SP concentrations that trigger the switch in humans are unknown. Only two dose levels were tested in each model, so the precise threshold between beneficial and harmful effects was not defined. Long-term outcomes of SP injection were not assessed.
How to read the evidence
This is a preclinical study combining in vitro stem cell experiments with an in vivo rat tendon injection model. While the dose-dependent effect is clearly demonstrated, translation to human tendinopathy treatment requires further research.
When this study was published
Published in 2015, this study established the dose-dependent paradigm for Substance P in tendinopathy that has influenced subsequent research on neuropeptide roles in tendon biology.
The bigger picture
This study contributes to the growing understanding that neuropeptides like Substance P are not simply 'pain molecules' but complex regulators of tissue repair and stem cell fate. The dose-dependent switch from regenerative to degenerative effects is a pattern seen with other signaling molecules and has important implications for the emerging field of regenerative medicine targeting tendons.
Questions still open
- What is the exact dose threshold at which Substance P switches from promoting tendon healing to causing tendinosis-like damage?
- Could controlled low-dose Substance P delivery be developed as a therapy for chronic tendinopathy?
- Do anti-Substance P therapies (NK1 receptor antagonists) used for other conditions inadvertently impair tendon healing?
Common questions
Why would a pain-related peptide also be involved in tendon healing?
What does this mean for treating tendon injuries?
Read the original research
The effects of substance p on tendinopathy are dose-dependent: an in vitro and in vivo model study.
The journal of nutrition, health & aging, 19(5), 555-61
Citation
Zhou, Y; Zhou, B; Tang, K. (2015). The effects of substance p on tendinopathy are dose-dependent: an in vitro and in vivo model study.. The journal of nutrition, health & aging, 19(5), 555-61. https://doi.org/10.1007/s12603-014-0576-3